Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | CTSK | P43235 | 10/20 | 0.45 |
| ▸ | CTSS | P25774 | 6/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | CA7 | P43166 | 1/20 | 0.45 |
| ▸ | CTSL | P07711 | 2/20 | 0.43 |
| ▸ | CTSB | P07858 | 1/20 | 0.43 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.43 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.43 |
| ▸ | RELA | Q04206 | 1/20 | 0.43 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | GSTP1 | P09211 | 1/20 | 0.40 |
| ▸ | GSTM2 | P28161 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1519852 | 1.00 | CYP1A2 (0.46) | CYP1A2CYP2C9CYP2C19HTTCTSK | |
| SCHEMBL1712024 | 1.00 | CYP1A2 (0.46) | CYP1A2CYP2C9CYP2C19HTTCTSK | |
| SCHEMBL31430920 | 0.98 | CYP1A2 (0.44) | CYP1A2CYP2C9CYP2C19HTTCTSK | |
| SCHEMBL27873036 | 0.98 | CYP1A2 (0.44) | CYP1A2CYP2C9CYP2C19HTTCTSK | |
| SCHEMBL27873038 | 0.98 | CYP1A2 (0.44) | CYP1A2CYP2C9CYP2C19HTTCTSK | |
| SCHEMBL3926315 | 0.91 | CYP1A2 (0.47) | CYP1A2CYP2C9CYP2C19HTTCTSK | |
| SCHEMBL3926306 | 0.91 | CYP1A2 (0.47) | CYP1A2CYP2C9CYP2C19HTTCTSK | |
| SCHEMBL27018510 | 0.91 | CYP1A2 (0.47) | CYP1A2CYP2C9CYP2C19HTTCTSK | |
| SCHEMBL5147608 | 0.86 | CYP1A2 (0.61) | CYP1A2CYP2C9CYP2C19HTTCTSK | |
| SCHEMBL1338105 | 0.86 | CTSK (0.44) | CYP1A2CYP2C9CYP2C19HTTCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 269 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116606237-A | Synthesis method of tryptophan derivative | 上海吉奉生物科技有限公司 | 2023-08-18 | — | — | CN | claimed |
| US-5876492-A | Ink compositions containing esters | XEROX CORPORATION (US) | 1999-03-02 | — | — | US | claimed |
| US-20260108546-A1 | GIP RECEPTOR AGONIST COMPOUNDS | LILLY CO ELI (US) | 2026-04-23 | — | — | US | disclosed |
| EP-4142732-B1 | METHODS OF USE FOR PYRIMIDINES AS FERROPORTIN INHIBITORS | GLOBAL BLOOD THERAPEUTICS INC (US) | 2026-04-22 | — | — | EP | disclosed |
| US-20260098060-A1 | MACROCYCLIC CFTR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2026-04-09 | — | — | US | disclosed |
| US-20260091048-A1 | GIP RECEPTOR AGONIST COMPOUNDS | LILLY CO ELI (US) | 2026-04-02 | — | — | US | disclosed |
| EP-4703362-A1 | COMPOUND CONTAINING OXO-PYRIDO-ALIPHATIC RING OR ALIPHATIC HETEROCYCLIC STRUCTURE, AND MEDICAL USE THEREOF | Chengdu Sibeibo Pharmaceutical Technology Co., Ltd (CN) | 2026-03-04 | — | — | EP | disclosed |
| US-20260015337-A1 | COMPOUNDS FOR TREATMENT A CORONAVIRUS INFECTION | TRAWSFYNYDD THERAPEUTICS INC (US) | 2026-01-15 | — | — | US | disclosed |
| US-20260008758-A1 | LINEAR DIPEPTIDYL PEPTIDASE 1 INHIBITORS AND USES THEREOF | INSMED INCORPORATED | 2026-01-08 | — | — | US | disclosed |
| US-20260001924-A1 | NEMO COILED COIL MIMICS AND METHODS OF USING SAME | NEW YORK UNIVERSITY (US) | 2026-01-01 | — | — | US | disclosed |
| WO-2025264954-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ALEXION PHARMACEUTICALS, INC. (US) | 2025-12-26 | — | — | WO | disclosed |
| WO-2003020688-A1 | SELECTIVE PROTEIN TYROSINE PHOSPHATASE INHIBITORS | ABBOTT LABORATORIES (US) | 2003-03-13 | — | — | WO | disclosed |
| US-20020173503-A1 | Substituted pyridoindoles as serotonin agonists and antagonists | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-11-21 | — | — | US | disclosed |
| US-20020169157-A1 | Selective protein tyrosine phosphatatase inhibitors | ABBOTT LABORATORIES | 2002-11-14 | — | — | US | disclosed |
| US-20020072516-A1 | Selective protein tyrosine phosphatatase inhibitors | ABBVIE INC. | 2002-06-13 | — | — | US | disclosed |
| EP-0903382-A1 | Semi-solid hot melt ink compositions containing esters | XEROX CORPORATION (US) | 1999-03-24 | — | — | EP | disclosed |
| US-5876492-A | Ink compositions containing esters | XEROX CORPORATION (US) | 1999-03-02 | — | — | US | disclosed |
| US-5710139-A | Heterocyclic compounds | ASTRA AB (SE) | 1998-01-20 | — | — | US | disclosed |
| EP-0736032-A1 | HETEROCYCLIC COMPOUNDS | Astra Aktiebolag (SE) | 1996-10-09 | — | — | EP | disclosed |
| WO-1995017410-A1 | HETEROCYCLIC COMPOUNDS | ASTRA AKTIEBOLAG (SE) | 1995-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020173503-A1 | Substituted pyridoindoles as serotonin agonists and antagonists | HTR1A, HTR1B, HTR7 | CYP1A2 365/4885CYP2C9 257/4885CYP2C19 127/4885 |
| US-20260098060-A1 | MACROCYCLIC CFTR MODULATORS | CFTR, CLIC1, ARRB1 | CYP1A2 1418/4885CYP2C9 1543/4885CYP2C19 1635/4885 |
| US-20260015337-A1 | COMPOUNDS FOR TREATMENT A CORONAVIRUS INFECTION | ACE2, ACE, TMPRSS2 | CYP1A2 210/4885CYP2C9 136/4885CYP2C19 94/4885 |
| US-20260091048-A1 | GIP RECEPTOR AGONIST COMPOUNDS | GIPR, GLP1R, GPR119 | CYP1A2 2194/4885CYP2C9 1804/4885CYP2C19 1012/4885 |
| US-20260108546-A1 | GIP RECEPTOR AGONIST COMPOUNDS | GIPR, GLP1R, GCGR | CYP1A2 2494/4885CYP2C9 2074/4885CYP2C19 1576/4885 |
| US-20260001924-A1 | NEMO COILED COIL MIMICS AND METHODS OF USING SAME | DDX21, PHAX, RBX1 | CYP1A2 4720/4885CYP2C9 4759/4885CYP2C19 4852/4885 |
| US-20260008758-A1 | LINEAR DIPEPTIDYL PEPTIDASE 1 INHIBITORS AND USES THEREOF | DPP3, DPP7, DPP9 | CYP1A2 1348/4885CYP2C9 328/4885CYP2C19 839/4885 |
| US-20020169157-A1 | Selective protein tyrosine phosphatatase inhibitors | PPM1B, PPM1A, PPM1D | CYP1A2 3344/4885CYP2C9 3213/4885CYP2C19 2802/4885 |
| US-20020072516-A1 | Selective protein tyrosine phosphatatase inhibitors | PPM1B, PPM1A, PPM1D | CYP1A2 3344/4885CYP2C9 3213/4885CYP2C19 2802/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.